From genome to drug lead: Identification of a small-molecule inhibitor of the SARS virus

Abstract Virtual screening, a fast, computational approach to identify drug leads [Perola, E.; Xu, K.; Kollmeyer, T. M.; Kaufmann, S. H.; Prendergast, F. G. J. Med. Chem. 2000, 43, 401; Miller, M. A. Nat. Rev. Drug Disc. 2002, 1 220], is limited by a known challenge in crystallographically determining flexible regions of proteins. This approach has not been able to identify active inhibitors of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) using solely the crystal structures of a SARS-CoV cysteine proteinase with a flexible loop in the active site [Yang, H. T.; Yang, M. J.; Ding, Y.; Liu, Y. W.; Lou, Z. Y. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 13190; Jenwitheesuk, E.; Samudrala, R. Bioorg. Med. Chem. Lett. 2003, 13, 3989; Rajnarayanan, R. V.; Dakshanamurthy, S.; Pattabiraman, N. Biochem. Biophys. Res. Commun. 2004, 321, 370; Du, Q.; Wang, S.; Wei, D.; Sirois, S.; Chou, K. Anal. Biochem. 2005, 337, 262; Du, Q.; Wang, S.; Zhu, Y.; Wei, D.; Guo, H. Peptides 2004, 25, 1857; Lee, V.; Wittayanarakul, K.; Remsungenen, T.; Parasuk, V.; Sompornpisut, P. Science (Asia) 2003, 29, 181; Toney, J.; Navas-Martin, S.; Weiss, S.; Koeller, A. J. Med. Chem. 2004, 47, 1079; Zhang, X. W.; Yap, Y. L. Bioorg. Med. Chem. 2004, 12, 2517]. This article demonstrates a genome-to-drug-lead approach that uses terascale computing to model flexible regions of proteins, thus permitting the utilization of genetic information to identify drug leads expeditiously. A small-molecule inhibitor of SARS-CoV, exhibiting an effective concentration (EC50) of 23μM in cell-based assays, was identified through virtual screening against a computer-predicted model of the cysteine proteinase. Screening against two crystal structures of the same proteinase failed to identify the 23-μM inhibitor. This study suggests that terascale computing can complement crystallography, broaden the scope of virtual screening, and accelerate the development of therapeutics to treat emerging infectious diseases such as SARS and Bird Flu.

[1]  H. Hsieh,et al.  Evaluation of metal‐conjugated compounds as inhibitors of 3CL protease of SARS‐CoV , 2004, FEBS Letters.

[2]  Kuo-Chen Chou,et al.  Molecular modeling and chemical modification for finding peptide inhibitor against severe acute respiratory syndrome coronavirus main proteinase , 2004, Analytical Biochemistry.

[3]  K. Chou,et al.  Polyprotein cleavage mechanism of SARS CoV Mpro and chemical modification of the octapeptide , 2004, Peptides.

[4]  Jindrich Cinatl,et al.  HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus , 2004, Biochemical and Biophysical Research Communications.

[5]  Jindrich Cinatl,et al.  Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines , 2004, Biochemical and Biophysical Research Communications.

[6]  A. Velázquez‐Campoy,et al.  Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro. , 2004, Biochemistry.

[7]  C. Peters,et al.  Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) , 2004, Virology.

[8]  S H Kaufmann,et al.  Successful virtual screening of a chemical database for farnesyltransferase inhibitor leads. , 2000, Journal of medicinal chemistry.

[9]  N. Pattabiraman,et al.  “Teaching old drugs to kill new bugs”: structure-based discovery of anti-SARS drugs , 2004, Biochemical and Biophysical Research Communications.

[10]  Y. Pang,et al.  Discovery of a new inhibitor lead of adenovirus proteinase: steps toward selective, irreversible inhibitors of cysteine proteinases , 2001, FEBS letters.

[11]  J. Ziebuhr,et al.  Characterization of a human coronavirus (strain 229E) 3C-like proteinase activity , 1995, Journal of virology.

[12]  Hao Chen,et al.  Virtual Screening of Novel Noncovalent Inhibitors for SARS-CoV 3C-like Proteinase , 2005, J. Chem. Inf. Model..

[13]  Christian Drosten,et al.  Identification of a novel coronavirus in patients with severe acute respiratory syndrome. , 2003, The New England journal of medicine.

[14]  M. Otto,et al.  Inhibition of Severe Acute Respiratory Syndrome-Associated Coronavirus (SARSCoV) by Calpain Inhibitors and β-D-N4-Hydroxycytidine , 2004, Antiviral chemistry & chemotherapy.

[15]  G. Gao,et al.  The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Y. Yap,et al.  Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs , 2004, Bioorganic & Medicinal Chemistry.

[17]  Christian Drosten,et al.  Cinanserin Is an Inhibitor of the 3C-Like Proteinase of Severe Acute Respiratory Syndrome Coronavirus and Strongly Reduces Virus Replication In Vitro , 2005, Journal of Virology.

[18]  Obi L. Griffith,et al.  The Genome Sequence of the SARS-Associated Coronavirus , 2003, Science.

[19]  Ram Samudrala,et al.  Identifying inhibitors of the SARS coronavirus proteinase , 2003, Bioorganic & Medicinal Chemistry Letters.

[20]  Marc Van Ranst,et al.  In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine , 2004, Biochemical and Biophysical Research Communications.

[21]  Andreas Koeller,et al.  Sabadinine: a potential non-peptide anti-severe acute-respiratory-syndrome agent identified using structure-aided design. , 2004, Journal of medicinal chemistry.

[22]  Y. Pang.  Three‐dimensional model of a substrate‐bound SARS chymotrypsin‐like cysteine proteinase predicted by multiple molecular dynamics simulations: Catalytic efficiency regulated by substrate binding , 2004, Proteins.

[23]  Mitchell A. Miller.  Chemical database techniques in drug discovery , 2002, Nature Reviews Drug Discovery.

[24]  Christian Drosten,et al.  Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome , 2003, Science.

[25]  Eric D. Brown,et al.  High-Throughput Screening Identifies Inhibitors of the SARS Coronavirus Main Proteinase , 2004, Chemistry & Biology.

[26]  K. Yuen,et al.  Characterization of SARS‐CoV main protease and identification of biologically active small molecule inhibitors using a continuous fluorescence‐based assay , 2004, FEBS Letters.

[27]  Yuan-Ping Pang,et al.  EUDOC: a computer program for identification of drug interaction sites in macromolecules and drug leads from chemical databases , 2001, J. Comput. Chem..